GlobeNewswire: Nemaura Medical Inc Contains the last 10 of 44 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:22:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/11/1983085/0/en/Nemaura-Medical-Reports-Results-and-Provides-Business-Update-for-the-Third-Quarter-Ended-December-31-2019.html?f=22&fvtc=4&fvtv=49571Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 20192020-02-11T14:00:00Z<![CDATA[Loughborough, England, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and financial results for the third quarter ended December 31, 2019.]]>https://www.globenewswire.com/news-release/2019/12/20/1963507/0/en/Nemaura-Provides-2019-Year-End-Corporate-Update.html?f=22&fvtc=4&fvtv=49571Nemaura Provides 2019 Year-End Corporate Update2019-12-20T14:00:00Z<![CDATA[Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update.]]>https://www.globenewswire.com/news-release/2019/12/17/1961636/0/en/Nemaura-Medical-and-Changing-Health-announce-Partnership-to-provide-award-winning-Diabetes-Behavioral-Change-services.html?f=22&fvtc=4&fvtv=49571Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services 2019-12-17T14:15:00Z<![CDATA[Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes]]>https://www.globenewswire.com/news-release/2019/12/05/1956786/0/en/Nemaura-Medical-announces-expansion-of-SugarBEAT-offering-with-BEAT-Diabetes-digital-subscription-services.html?f=22&fvtc=4&fvtv=49571Nemaura Medical announces expansion of SugarBEAT® offering with BEAT® Diabetes digital subscription services2019-12-05T13:30:00Z<![CDATA[BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients]]>https://www.globenewswire.com/news-release/2019/12/04/1956283/0/en/Nemaura-Medical-Announces-1-for-10-Reverse-Split-Intended-to-Attract-a-Wider-Universe-of-Institutional-Investors.html?f=22&fvtc=4&fvtv=49571Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors2019-12-04T15:00:00Z<![CDATA[Loughborough, England, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced plans to conduct reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share on a one 1 for 10 basis. The reverse split is expected to take effect at the market open on December 5, 2019. The new CUSIP number will be 640442208.]]>https://www.globenewswire.com/news-release/2019/11/11/1944726/0/en/Nemaura-Medical-Reports-Results-and-Provides-Business-Update-for-the-Second-Quarter-Ended-September-30-2019.html?f=22&fvtc=4&fvtv=49571Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 20192019-11-11T14:00:00Z<![CDATA[Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019.]]>https://www.globenewswire.com/news-release/2019/10/03/1924753/0/en/Nemaura-Medical-Provides-Update-Regarding-Commercial-Launch-of-SugarBEAT-and-First-Patient-User-Experiences-as-Presented-at-EASD-Symposia-2019-in-Barcelona.html?f=22&fvtc=4&fvtv=49571Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona2019-10-03T13:00:00Z<![CDATA[Loughborough, England, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona.]]>https://www.globenewswire.com/news-release/2019/09/12/1914854/0/en/Nemaura-Medical-to-Hold-a-Symposia-at-EASD-in-Barcelona-on-Thursday-September-19-2019.html?f=22&fvtc=4&fvtv=49571Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 20192019-09-12T13:15:00Z<![CDATA[Loughborough, England , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that Dr. Faz Chowdhury, Chief Executive Officer, Dr. Fred Schaebsdau, VP Strategic Alliances, and Dr Iain Cranson, a diabetes specialist based in the UK, will be presenting at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) on Thursday, September 19, 2019 at 18:45 - 20:15 Central European Time at the Fira Barcelona Gran Via (Maimonides Hall) in Barcelona, Spain. The evening symposia will focus on the historic development of SugarBEAT®, its application to all categories of diabetics and diabetes management, clinical data and recent user experiences. The presentation is titled: “SugarBEAT® Non-Invasive CGM User Study Results: Diagnostic and Monitoring Applications Across Different Patient Types and Clinical Settings.”]]>https://www.globenewswire.com/news-release/2019/08/09/1900068/0/en/Nemaura-Medical-Reports-Quarterly-Results-for-First-Quarter-Ended-June-30-2019.html?f=22&fvtc=4&fvtv=49571Nemaura Medical Reports Quarterly Results for First Quarter Ended June 30, 20192019-08-09T17:30:00Z<![CDATA[Loughborough, England, Aug. 09, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the first quarter ended June 30, 2019.]]>https://www.globenewswire.com/news-release/2019/08/07/1898346/0/en/Nemaura-Medical-Announces-First-Shipments-of-SugarBEAT-Devices-to-Diabetic-and-Pre-Diabetic-Patients-as-Part-of-its-First-Phase-of-Launch.html?f=22&fvtc=4&fvtv=49571Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch2019-08-07T12:30:00Z<![CDATA[Reports strong pre-launch consumer interest with over 17,000 potential users that have signed up to receive product information prior to launch of official marketing campaign Reports strong pre-launch consumer interest with over 17,000 potential users that have signed up to receive product information prior to launch of official marketing campaign]]>